Top buyers by activity, Q1-Q3 2012

Tools

The company: Valeant Pharmaceuticals ($VRX)
# deals: 6
Total: $3.3 billion
Acquired: Medicis Pharmaceutical; OraPharma; Natur Produkt; Eyetech Inc.; Probiotica, Pedinol Pharmacal

The company: Amgen ($AMGN)
# deals: 3
Total: $2.17B
Acquired: KAI Pharmaceuticals; Mustafa Nevzat Pharmaceuticals; Micromet   

The company: Bristol-Myers Squibb ($BMY)
# deals: 2
Total: $7.8B
Acquired: Amylin, Inhibitex

Company: GlaxoSmithKline ($GSK)
# deals: 2
Total: $3.7B
Acquired: Human Genome Sciences; Cellzome

Company: Dainippon Pharmaceutical
# deals: 2
Total: $3B
Acquired: Boston Biomedical, Reichhold Chemicals

      

The company: Perrigo
# deals: 2
Total: $321 million
Acquired: Finetech, Sergeant's Pet Care Products

The company: Takeda
# deals: 2
Total: $267M
Acquired: Multilab; URL Pharma; (added Envoy Therapeutics in October)

The company: Qiagen
# deals: 2
Total: $160M
Acquired: AmniSure International; Ipsogen

The company: Paladin Labs
# deals: 2
Total: $76 million
Acquired: Pharmaplan; Litha Healthcare Group

The company: Opko Health
# of deals: 2
Total: $21M
Acquired: Finetech

 

Special Report: The top M&A dealmakers in biopharma
  • (Unpublished)